FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093510433> ?p ?o ?g. }

• W2093510433 endingPage "163" @default.
• W2093510433 startingPage "155" @default.
• W2093510433 abstract "Propos. – La maladie de Castleman est une prolifération lymphoplasmocytaire polyclonale et vasculaire prédominant au sein des structures lymphoïdes. Elle associe des adénopathies diffuses, une hépatosplénomégalie et une fièvre. Ces manifestations correspondent à un tableau d’hypersécrétion d’IL-6. Le pronostic est sombre. Les infections opportunistes, propre au terrain sida aggravent ce pronostic. Les monochimiothérapies prolongées, par vinblastine ou étoposide, contrôlent la maladie de Castleman. Actualités et points forts. – Les récents progrès concernant le virus HHV8 (Human Herpesvirus 8) et sa présence dans les formes liées au VIH ont permis d’expliquer l’ensemble des manifestations de la maladie de Castleman. En effet, le virus HHV8 produit un homologue de l’IL-6, la vIL-6, responsable d’une prolifération lymphoplasmocytaire polyclonale. La présence d’autres homologues de cytokines humaines, produites par le virus HHV8, pourrait également participer à la prolifération lymphoplasmocytaire et endothéliale. Perspectives et projets. – Compte tenu de son origine virale, un traitement par interféron alpha pourrait être une alternative dans les formes peu évolutives. Cependant, les traitements antiviraux visant le virus HHV8 ou le VIH et la reconstitution immunitaire n’ont aucune influence sur l’évolution de la maladie de Castleman, à l’inverse des infections opportunistes. Purpose. – Castleman’s disease is a polyclonal lymphoplasmacytic and vascular proliferation prominant in lymphoid tissues. It is associated with lymph node enlargement, hepatosplenomegaly and fever. This manifestations could be secondary to hyperproduction of interleukin 6. The prognosis is poor. The opportunistic infections which are characteristic of severe HIV infection worsen the prognosis. Prolonged monochemotherapy with vinblastine or etoposide can control Castleman’s disease. Current knowledge and key points. – Recent advances in human herpesvirus 8 (HHV8) knowledge and its predominance in the forms which are linked to the HIV seropositivity have partly explained the clinical manifestations of Castleman’s disease. Indeed, HHV8 produce an homologous interleukin 6, the vIL-6, responsible for lymphoplasmacytic proliferation. The presence of other homologues of human cytokines produced by HHV8 could contribute to lymphoplasmacytosis and to endothelial proliferation. Future and prospects. – Taking into account this viral origin, alpha interferon could be an alternative in forms which are less progressive. However, antiviral therapy against HHV8 or HIV and the immunitary restoration do not have any influence on the evolution of Castleman’s disease, contrary to opportunistic infections." @default.
• W2093510433 created "2016-06-24" @default.
• W2093510433 creator A5004949197 @default.
• W2093510433 creator A5009181226 @default.
• W2093510433 creator A5029295800 @default.
• W2093510433 creator A5030129204 @default.
• W2093510433 creator A5049530249 @default.
• W2093510433 creator A5053093893 @default.
• W2093510433 creator A5065962319 @default.
• W2093510433 creator A5068313245 @default.
• W2093510433 creator A5071791274 @default.
• W2093510433 date "2002-02-01" @default.
• W2093510433 modified "2023-10-16" @default.
• W2093510433 title "Maladie de Castleman chez les patients infectés par le VIH" @default.
• W2093510433 cites W150778959 @default.
• W2093510433 cites W1632068222 @default.
• W2093510433 cites W1679234458 @default.
• W2093510433 cites W1928973808 @default.
• W2093510433 cites W1967340335 @default.
• W2093510433 cites W1970339166 @default.
• W2093510433 cites W1974486772 @default.
• W2093510433 cites W1982047106 @default.
• W2093510433 cites W1987091861 @default.
• W2093510433 cites W2002856652 @default.
• W2093510433 cites W2009417193 @default.
• W2093510433 cites W2013041881 @default.
• W2093510433 cites W2017240364 @default.
• W2093510433 cites W2021624909 @default.
• W2093510433 cites W2023972192 @default.
• W2093510433 cites W2029056420 @default.
• W2093510433 cites W2032438721 @default.
• W2093510433 cites W2040101410 @default.
• W2093510433 cites W2045982793 @default.
• W2093510433 cites W2064192992 @default.
• W2093510433 cites W2070489933 @default.
• W2093510433 cites W2070570111 @default.
• W2093510433 cites W2071800809 @default.
• W2093510433 cites W2072338993 @default.
• W2093510433 cites W2075681466 @default.
• W2093510433 cites W2093149798 @default.
• W2093510433 cites W2097465667 @default.
• W2093510433 cites W2104949735 @default.
• W2093510433 cites W2109249128 @default.
• W2093510433 cites W2124597427 @default.
• W2093510433 cites W2137819483 @default.
• W2093510433 cites W2151835154 @default.
• W2093510433 cites W2160048836 @default.
• W2093510433 cites W2160409151 @default.
• W2093510433 cites W219613607 @default.
• W2093510433 cites W2206048520 @default.
• W2093510433 cites W2280492586 @default.
• W2093510433 cites W2322571793 @default.
• W2093510433 cites W2323477045 @default.
• W2093510433 cites W2328705550 @default.
• W2093510433 cites W2331249260 @default.
• W2093510433 cites W2336241188 @default.
• W2093510433 cites W2341821782 @default.
• W2093510433 cites W2410723119 @default.
• W2093510433 cites W2588036151 @default.
• W2093510433 cites W321874077 @default.
• W2093510433 cites W4230624801 @default.
• W2093510433 cites W43146481 @default.
• W2093510433 cites W74632471 @default.
• W2093510433 doi "https://doi.org/10.1016/s0248-8663(01)00531-8" @default.
• W2093510433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11876059" @default.
• W2093510433 hasPublicationYear "2002" @default.
• W2093510433 type Work @default.
• W2093510433 sameAs 2093510433 @default.
• W2093510433 citedByCount "12" @default.
• W2093510433 countsByYear W20935104332016 @default.
• W2093510433 countsByYear W20935104332017 @default.
• W2093510433 countsByYear W20935104332023 @default.
• W2093510433 crossrefType "journal-article" @default.
• W2093510433 hasAuthorship W2093510433A5004949197 @default.
• W2093510433 hasAuthorship W2093510433A5009181226 @default.
• W2093510433 hasAuthorship W2093510433A5029295800 @default.
• W2093510433 hasAuthorship W2093510433A5030129204 @default.
• W2093510433 hasAuthorship W2093510433A5049530249 @default.
• W2093510433 hasAuthorship W2093510433A5053093893 @default.
• W2093510433 hasAuthorship W2093510433A5065962319 @default.
• W2093510433 hasAuthorship W2093510433A5068313245 @default.
• W2093510433 hasAuthorship W2093510433A5071791274 @default.
• W2093510433 hasConcept C142724271 @default.
• W2093510433 hasConcept C2776054410 @default.
• W2093510433 hasConcept C2779134260 @default.
• W2093510433 hasConcept C29456083 @default.
• W2093510433 hasConcept C71924100 @default.
• W2093510433 hasConceptScore W2093510433C142724271 @default.
• W2093510433 hasConceptScore W2093510433C2776054410 @default.
• W2093510433 hasConceptScore W2093510433C2779134260 @default.
• W2093510433 hasConceptScore W2093510433C29456083 @default.
• W2093510433 hasConceptScore W2093510433C71924100 @default.
• W2093510433 hasIssue "2" @default.
• W2093510433 hasLocation W20935104331 @default.
• W2093510433 hasLocation W20935104332 @default.
• W2093510433 hasOpenAccess W2093510433 @default.
• W2093510433 hasPrimaryLocation W20935104331 @default.
• W2093510433 hasRelatedWork W1506200166 @default.

• next